Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) fell 4% during mid-day trading on Tuesday . The stock traded as low as $13.81 and last traded at $13.67. 770,893 shares changed hands during trading, a decline of 20% from the average session volume of 959,814 shares. The stock had previously closed at $14.23.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on LQDA. HC Wainwright restated a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Finally, Needham & Company LLC reissued a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $26.63.
Check Out Our Latest Stock Analysis on Liquidia
Liquidia Stock Performance
The firm has a market cap of $1.35 billion, a PE ratio of -9.71 and a beta of 0.24. The stock has a 50-day simple moving average of $14.22 and a two-hundred day simple moving average of $13.01.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, sell-side analysts anticipate that Liquidia Co. will post -1.51 EPS for the current fiscal year.
Insider Activity at Liquidia
In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This trade represents a 1.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the sale, the insider now owns 263,152 shares in the company, valued at approximately $3,597,287.84. This represents a 0.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,138 shares of company stock worth $450,233. Corporate insiders own 30.10% of the company's stock.
Institutional Investors Weigh In On Liquidia
A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in Liquidia by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the fourth quarter valued at $59,000. Summit Investment Advisors Inc. grew its stake in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after buying an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia in the 4th quarter worth about $142,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Liquidia in the 4th quarter worth about $154,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
